# TRIANA Biomedicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triana-biomedicines-2

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.trianabio.com
- Total disclosed funding: $179M
- Latest round: Series B (Nov 26, 2025)
- Investors on record: 12

## About

TRIANA Biomedicines, Inc., based in the US, focuses on innovative therapeutic solutions utilizing proprietary molecular glue technology to enhance protein interactions and target disease pathways, with a strong emphasis on oncology.TRIANA Biomedicines, Inc. is dedicated to the discovery and development of therapeutics leveraging its unique molecular glue technology. The company, headquartered in Lexington, US, has navigated strategic pivots to enhance its offerings. In December 2025, TRIANA raised USD 120.00 mn in Series B funding, co-led by Ascenta Capital and Bessemer Venture Partners, to propel its clinical developments. The founder's history is not publicly detailed, and there are no mentions of any parent companies or subsidiaries.TRIANA Biomedicines specializes in the discovery and development of innovative therapeutics through its proprietary molecular glue technology. The company's core product offerings focus on small molecules that enhance protein-protein interactions, forming ternary complexes that can impact disease pathways, particularly in the realm of targeted protein degradation. With an emphasis on cancer treatment, TRIANA aims to address disease targets that have historically been deemed undruggable. The company focuses its efforts in diverse global markets, primarily targeting regions with strong pharmaceutical infrastructures, including North America, Europe, and parts of Asia. The end users of TRIANA's products include healthcare professionals and institutions involved in oncology, seeking novel therapeutic options for their patients.TRIANA Biomedicines generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and research institutions. These agreements involve licensing its molecular glue technology and co-development of therapeutic candidates. Transactions typically occur through structured collaboration models, where financial terms are based on milestones and outcomes related to drug development. The revenue structure may include upfront payments, milestone payments upon achieving specific clinical or regulatory outcomes, and royalties on future sales of any products developed from these collaborations. TRIANA's proprietary technology and its focus on targeted therapies position it within the biopharmaceutical landscape, facilitating partnerships that drive its financial growth and enhance its market presence.In December 2025, TRIANA Biomedicines, Inc. raised USD 120.00 mn in Series B funding to advance its lead candidate, TRI-611, to clinical proof of concept for ALK+ NSCLC. The company plans to select a second product candidate in 2026 and accelerate the development of its pipeline programs. The recent funding will support these initiatives, enabling TRIANA to strengthen its position in targeted therapies and expand its reach into new markets.

## Funding rounds

- Series B, Nov 26, 2025, $120M — Atlas Venture, Lightspeed Venture Partners, Bessemer Venture Partners, Surveyor Capital, Pfizer Venture Investments, Invus Financial Advisors, RA Capital Management, Ascenta Capital, YK Bioventures, Regeneron Ventures, Finchley Healthcare Ventures
- Series A, Apr 19, 2022, $7.8M — Atlas Venture, Lightspeed Venture Partners, Surveyor Capital, Pfizer Venture Investments, RA Capital Management, Logos Capital
- Series A, Jan 28, 2022, $35M — Atlas Venture, Lightspeed Venture Partners, RA Capital Management
- Seed, Sep 3, 2021, $10M — Atlas Venture, RA Capital Management
- Seed, May 22, 2020, $6M — RA Capital Management

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed, Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series B
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A, Series B
- Surveyor Capital — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series B
- YK Bioventures (https://capitalatlas.ai/funds/yk-bioventures) — Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series B
- Finchley Healthcare Ventures (https://capitalatlas.ai/funds/finchley-healthcare-ventures) — Series B